Dr. Zamarin on the Future Treatment Landscape of Gynecologic Malignancies

Dmitriy Zamarin, MD, PhD
Published: Friday, Oct 13, 2017



Dmitriy Zamarin, MD, PhD, a medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the future treatment landscape for patients with gynecologic malignancies.

According to Zamarin, the first drugs that will be approved will be more of the standard off-the-shelf treatments, such as immune checkpoint blockade or vaccines.

The adoptive T-cell therapies will be are more involved and more expensive, states Zamarin. The recent product that was approved from Novartis for the treatment of patients with leukemia is very expensive per treatment, which may become a limitation of choosing some of these therapies. If the therapies resolve in long-term disease stabilization or even cures of these patients, perhaps these types of treatments will justify the costs, explains Zamarin.
 


Dmitriy Zamarin, MD, PhD, a medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the future treatment landscape for patients with gynecologic malignancies.

According to Zamarin, the first drugs that will be approved will be more of the standard off-the-shelf treatments, such as immune checkpoint blockade or vaccines.

The adoptive T-cell therapies will be are more involved and more expensive, states Zamarin. The recent product that was approved from Novartis for the treatment of patients with leukemia is very expensive per treatment, which may become a limitation of choosing some of these therapies. If the therapies resolve in long-term disease stabilization or even cures of these patients, perhaps these types of treatments will justify the costs, explains Zamarin.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x